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Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the
chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a
good quality of life. Despite its beneficial effects, Imatinib has significant side effects such as mucosal pigmentation. A 72-year-old
female having an Imatinib induced mucosal pigmentation is presented: she has been treated with Imatinib since 2003 and only in
2014 discovered, during a routine dental visit, having a pigmented lesion on her hard palate mucosa. Histopathologically, the lesion
shows the deposition of fine dark brown spherical bodies within the lamina propria and cloaked in between the collagen fibers.
There was no sign of inflammation, hyperplasia, or hemorrhage in the tissue.
1. Introduction
Pigmented lesions of the oral cavity are common oral lesions
that may present as a solitary lesion, as a manifestation of
systemic pathology, or as a collateral effect of drug therapy
[1]. The etiology of oral pigmentation may range from simple
benign lesions, such as a blue nevus, to complex and malig-
nant disorders, such as oral melanoma. The differential diag-
nosis includes physiological pigmentation such as those typ-
ically seen in African Americans, postinflammatory melano-
sis, amalgam tattoo, smoking related pigmentation, blue
nevus, and malignant melanoma. Peutz-Jeghers syndrome,
Addison disease, and some other rare diseases, such as poly-
ostotic dysplasia, hyperthyroidism, and Nelson syndrome,
could be also associated with an oral pigmented lesion.
Moreover, a number of drugs, such as antimalarials,
tetracyclines, and antiretroviral and chemotherapeutic drugs,
may also cause oral pigmentations. One of these chemother-
apeutic drugs, Imatinib Mesylate, also known as Gleevec or
ST1-571, is a tyrosine-kinase inhibitor that targets Bcr-Abl
protein, c-Kit, and platelet derived growth factor receptor
and is used as a first-line treatment for chronic myeloid
leukemia (CML) and gastrointestinal stromal tumor (GIST)
[2, 3]. Chronic myeloid leukemia is a slow-growing tumor
of white blood cells, characterized by an unregulated growth
of the myeloid precursor cells and its accumulation both in
the bone marrow and the lymphoid organs. Chronic myeloid
leukemia is more common inmales than females and appears
more in patients between 25 and 60 years. The cause of CML
is the translocation of regions of the BCR and ABL genes to
form a BCR-ABL fusion gene. In at least 90 percent of cases,
this event is a reciprocal translocation termed t(9;22), which
forms the Philadelphia (Ph) chromosome. The product of
the BCR-ABL gene, the BCR-ABL protein, is a constitutively
active protein tyrosine kinase with an important role in the
regulation of cell growth [4]; its presence is a strong indicator
for CML (since 95% of people with CML have it) but not
sufficient on its own for a diagnosis, because 30% of people
with ALL will also show Ph+ in their genome. The 9;22
translocation leads to a chimeric gene fusion through the
bonding of Abl-1 (Abelson) gene located on chromosome
9, with a part of the Bcr (breakpoint cluster region) on a
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Figure 1: Diffuse, blue-grey pigmented lesion of the hard palate
mucosa of our case.
truncated chromosome 22. This way, BCR-ABL acts as an
oncogene that overexpresses a tyrosine-kinase protein that
stimulates the leukemic growth of myeloblasts [5]. Chronic
myeloid leukemia has been treated for years with both
hydroxyurea and bone marrow transplant, which, until the
discovery of Imatinib, has been the only successful therapy in
70% of the cases.
With the introduction of Imatinib Mesylate (ST1-571 or
Gleevec) the therapeutic options have significantly improved.
This treatment modality allows most patients to have a
good quality of life when compared to the other chemother-
apy drugs [6–8]. Despite its enormous therapeutic effects,
Gleevec has very common adverse effects including nau-
sea, fluid retention, lowered resistance to infection (due
to neutropenia), and, sometimes, congestive cardiac failure.
Dermatological side effects have also been very common such
as rash, superficial edema, GVH-like disease, erythroderma,
and lichenoid eruptions. On the other hand, intraoral side
effects seem to be very rare, such as lichenoid reactions and
dental and oral mucosal pigmentation [9].
Herein we report a case of oral pigmentation involving
the hard palate mucosa in a patient on Imatinib therapy.
2. Case Report
A 72-year-old Spanish woman was referred in October 2014
from her regular dentist to the Unit of Oral Medicine,
Sapienza University of Rome, for evaluation of a pigmented
lesion on the hard palate mucosa. The lesion, discovered
during a routine dental examination, appeared as a single,
flat, painless lesion, with a blue-grey color, blurred edges, and
was located in the center of the hard palate mucosa. There
were areas of physiologic mucosa above the palatal raphe
(Figure 1). The patient was unaware of the lesion, and she
stated that she had no history of trauma to the hard palate.
Her medical history was significant for gastroesophageal
reflux disease (GERD), diuresis, and CML. She is being
treated with Imatinib Mesilate 400mg per day since 2003 for
CML. She is also taking medications for GERD (esomepra-
zole) and for diuresis (amiloride HCl-hydrochlorothiazide).
The patient stated she has never taken minocycline,
hydroxyurea, and/or antimalarial drugs. Furthermore she
reports she has never smoked or drank alcohol and has never
Figure 2: Palatal mucosa with a minor salivary gland containing
pigment within the lamina propria (HE ×40).
Figure 3: Fine spherical bodies lying in the lamina propria; absence
of hyperplasia or inflammation or hemorrhage (HE ×200).
been in contact with heavy metals. During the visit we did
not find any other pigmented lesion on the thorax/back, skin,
or the fingernails. An incisional biopsy of the hard palate
mucosa was scheduled and performed two weeks later. The
biopsy was executed by taking a square section of the right
hard palate mucosa representative of the lesion and fixed in
4% buffered formaldehyde. It was 10 × 4mm with a depth
measuring 2–4mm.
3. Histopathological Findings
Standard hematoxylin and eosin stained sections were per-
formed; the microscopic examination of the tissue showed a
squamous tissue and an underlying tissue containing aminor
salivary gland (Figure 2). There were no signs of cellular
atypia, melanocytic hyperplasia, hemorrhagic circumstances,
and inflammation. Hard palate mucosa showed the presence
of minimal brown spherical bodies located within the lamina
propria, lying in between the collagen fibers (Figures 3 and
4).
Established on clinical and histological data, the diagnosis
was mucosal pigmentation related to Imatinib Mesylate
therapy.
4. Discussion
The above patient after long-term use (11 years) of Ima-
tinib Mesylate developed a diffuse blue-grey pigmentation
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Figure 4: Fine spherical brown particles cloaked in between the
collagen fibers in the lamina propria (HE ×400).
of the hard palate mucosa. The lesion, histopathologically,
showed the presence of fine brown spherical particles within
the lamina propria, which were both positive for Prussian
blue and Fontana-Masson stains, indicating the presence
of hemosiderin and melanin, respectively. There was no
evidence ofmalignancy, and both the clinical and histopatho-
logical presentation confirmed the diagnosis of drug-related
melanosis of the mucosa, Imatinib in this case.
Imatinib Mesylate works by inhibiting BCR-ABL by
binding the ATP site in an “off mode” so that the enzymatic
activity of the protein is not catalyzed anymore [7, 8].
Dermatological side effects of Imatinib are common such
as rash, superficial edema, Graft Versus Host-like disease,
erythroderma, and lichenoid eruptions. Despite these com-
mon side effects, Gleevec has rarely been reported to produce
diffuse hyperpigmentation of the palatal mucosa.
Generally, medication-induced melanosis in the oral
mucosa can be attributed to any one of the following
mechanisms: pigmented breakdown of drug products, drugs
inducing melanin formation, or drug metabolites chelated
with iron and melanin.
The pathogenesis of oral mucosal pigmentation in
patients taking Imatinib still remains unclear; it has been sug-
gested that Imatinib blocks the binding on the c-kit receptors
(a growth factor receptor found on skin cell,melanocytes, and
mast cells) and subsequently alters both melanogenesis and
melanocyte homeostasis [2, 9]. However, pigmented deposi-
tions in the oral mucosa indicate much different pathologies
and are challenging to diagnose correctly. Differential diag-
nosis includes physiological pigmentation, amalgam tattoo,
melanotic macule, smoker’s melanosis, melanocytic nevus,
malignant melanoma, and drug-induced melanosis.
The two most common types of melanotic alteration
are physiological pigmentations, which are related to racial
melanosis (mostly diffuse changes on the attached gingiva)
and postinflammation melanosis, as a consequence of a
trauma.
Melanotic macule and melanocytic nevus are rare, but
in 90% of cases they are located in the hard palate mucosa,
which is why they were included in the differential diagnosis.
Pigmented lesions related to systemic diseases were
also considered. Addison’s disease and Peutz-Jeghers syn-
drome could lead to an oral melanosis condition such as
diffuse oral macules and oral ephelides [2–4, 10, 11]. In
regard to medication-related melanosis other than Imatinib-
antimalarials, minocycline, anti-inflammatory drugs for
treating leprosy, and conjugated estrogens are considered.
The reason why the melanin and iron accumulate in this
part of the oral cavity is still unknown; what is known is that
they accumulate due to drug metabolites that chelate them,
just like minocycline and antimalarial drugs do.
In summary we present a case of melanosis of the hard
palate mucosa related to Imatinib; the lesion is benign and
therefore no treatment is needed [2, 10, 11].
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